“Four years of remission with fulvestrant monotherapy in advanced endometrioid adenocarcinoma of the endometrium Harboring an ESR1 Mutation: A case Report”
Year: 2025
Type: article
Study design: Case Report
Abstract: •Progestin therapy is the preferred hormonal treatment for advanced endometrioid carcinoma.•Next-generation sequencing can aid decision-making in advanced disease.•ESR1 and CTNNB1 mutations are poor molecular prognostic factors.•Fulvestrant may be an option to treat patients with ESR1 mutations.
Source: Gynecologic Oncology Reports
Authors: João Felipe Feldmann, Karoline Duarte, João Henrique Feldmann, Mariana Carvalho Gouveia, Romulo Loss Mattedi, Fabio Payao Pereira, Mariana Scaranti
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $930
OpenAlex ID: W4409662650